Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
Veids | Citi |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2011-06-13 09:20:57 |
Versijas komentārs | |
Teksts |
Active pharmaceutical
ingredients UDCA*
manufacturing
unit is one of “Grindeks”
most significant investment
projects. The total
contribution of
the
new manufacturing unit
consists of 6.34
million
lats,
of which
2.8
million lats
is the
co-financing by the European
Regional
Development
Fund
(ERDF).
We
invite journalists
and
media
representatives to
attend
In the opening ceremony will take part the Prime Minister of the Republic of Latvia Valdis Dombrovskis, JSC “Grindeks” Chairman of the Council Kirovs Lipmans, JSC “Grindeks” Chairman of the Board Janis Romanovskis etc.
After the formal opening ceremony, there will be an excursion to the new manufacturing unit.
Journalists and media representatives are welcome to come to “Grindeks” by a special bus that will wait at 10.15 a. m. in the parking by the Riga Technical University on Kalku Street in Riga, but, please inform us about it in advance until 12 o’clock noon, 15 June by phones: 67083336 or 26466681.
Further
information:
Laila
Klavina
Head of
the Communications Department
JSC
“Grindeks”
Phones:
(+371)
67083370, (+371) 29256012
Fax:
(+371) 67083505
E-mail:
laila.klavina@grindeks.lv
*Active
pharmaceutical ingredient UDCA (ursodeoxycholic acid) is used for
production of final dosage forms in the treatment of hepatic and
gallstone diseases. It dissolves cholesterol gallstones, and
increases hepatocyte membrane stabilizing and resistance functions
during harmful exposure, restores damaged hepatocyte membranes,
inhibits the abnormal immune response in the liver at cholestatic
liver disease.
|
Pielikumi |
|